Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+0.36%
1,096.72
+3.98
+0.36%
—1,092.741,095.951,103.321,094.72——
SIXC
Communications
SIXC
Communications
SIXC
-0.33%
611.32
-2.04
-0.33%
—613.36613.36613.36609.50——
SIXE
Energy
SIXE
Energy
SIXE
-0.45%
1,171.54
-5.25
-0.45%
—1,176.791,176.521,182.251,166.69——
SIXI
Industrials
SIXI
Industrials
SIXI
-0.45%
1,747.63
-7.91
-0.45%
—1,755.541,759.231,766.301,746.04——
SIXM
Financials
SIXM
Financials
SIXM
-0.58%
631.49
-3.66
-0.58%
—635.15635.20636.89630.09——
SIXR
Staples
SIXR
Staples
SIXR
+0.23%
849.94
+1.93
+0.23%
—848.01852.52855.78849.58——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
+0.09%
218.06
+0.20
+0.09%
—217.86217.86219.52217.86——
SIXT
Technology
SIXT
Technology
SIXT
+3.47%
3,536.03
+118.68
+3.47%
—3,417.353,452.773,536.033,450.39——
SIXU
Utilities
SIXU
Utilities
SIXU
-0.91%
905.07
-8.29
-0.91%
—913.36915.10920.43904.57——
SIXV
Health care
SIXV
Health care
SIXV
-0.86%
1,449.86
-12.52
-0.86%
—1,462.381,461.131,464.531,446.02——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.30%
2,430.47
+7.33
+0.30%
—2,423.142,428.712,448.692,424.63——
Q1 2026 earnings • released • EPS beat +22.11% • Revenue miss -1.51%
See results
GRFS:NASDAQ
Grifols SA - ADR ADR Class B
$8.10
+0.50%
(+0.040) 1D
$8.10
0.00% (0.00)
After hours
Closed: May 8, 4:00:00 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GRFS...
Open
$8.16
High
$8.18
Low
$7.98
Mkt. cap
6.58B
Avg. vol.
700.18K
Volume
682.75K
Dividend
2.17%
Quarterly dividend
$0.04
Ex dividend date
Aug 11, 2025
P/E ratio
11.69
52-wk high
$11.14
52-wk low
$7.09
EPS
$0.69
Beta
0.68
Shares outstanding
261.42M
No. of employees
25K
News stories
From sources across the web
Profile
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30. Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
About Grifols SA - ADR ADR Class B
CEONacho Abia
Employees25.3K
FoundedNov 18, 1940
Headquarters-
SectorBiotechnology
Websitegrifols.com
Last report
May 7, 2026
Fiscal Period
Q1 2026
EPS / Est. (EUR)
€0.16 / €0.13
+22.11%beat
Revenue / Est. (EUR)
1.70B / 1.73B
-1.51%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
1.89B
1.87B
1.98B
1.70B
Cost of goods sold
1.15B
1.11B
1.28B
1.08B
Cost of revenue
1.15B
1.11B
1.28B
1.08B
Research and development expenses
96.19M
97.01M
90.82M
90.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
298.06M
273.76M
262.86M
281.00M
Operating expense
394.25M
370.34M
353.11M
371.00M
Total operating expenses
1.54B
1.48B
1.63B
1.45B
Operating income
349.54M
381.18M
347.38M
249.00M
Other non operating income
8.08M
-
-33.00M
-
EBT including unusual items
190.51M
198.13M
111.10M
112.00M
EBT excluding unusual items
190.51M
227.20M
183.10M
112.00M
Income tax expense
52.13M
54.71M
-14.68M
24.00M
Effective tax rate
27.36%
27.61%
-13.21%
21.43%
Other operating expenses
-
-430.00K
-570.00K
-
Net income
117.06M
126.96M
98.25M
73.00M
Net profit margin
6.19%
6.81%
4.96%
4.29%
Earnings per share
0.19
-
-
-
Interest and investment income
9.56M
-
36.00M
-
Interest expense
-141.43M
-156.07M
-107.99M
-139.00M
Net interest expenses
-131.88M
-156.07M
-71.99M
-139.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
414.24M
484.03M
422.88M
353.00M
Gain or loss from assets sale
732.00K
-
2.00M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer